Winrevair’s approval comes a few days after the FDA approved Johnson & Johnson’s Opsynvi, a fixed-dose combination of endothelin antagonist macitentan and PDE-5 inhibitor tadalafil.

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, rather than its symptoms, and has also been cleared in Europe and ...

At recent prices, the stock offers a 3.7% yield. Last March, the Food and Drug Administration (FDA) approved Winrevair, a treatment for adults with pulmonary arterial hypertension. Fourth-quarter ...

United Therapeutics shows strong revenue growth, driven by Tyvaso, and maintains high margins and low debt burden. Read why I ...

The company’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), has been granted priority review by the FDA for treating patients ... the successful launch of WINREVAIR and the robust performance ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Wall Street is generally afraid of uncertainty, but with adversity also comes opportunity. Find out my 2 picks that have well ...

In a significant development, the company announced that the US FDA has accepted for priority ... the successful roll-out of WINREVAIR and healthy performance of its Animal Health business.

Sales of new pulmonary arterial hypertension drug, Winrevair, also missed estimates ... is under review in the United States, with an FDA decision expected in June. Merck is heavily reliant ...